Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Post-marketing withdrawal of medicinal products because of deaths can be occasioned by evidence obtained from case reports, observational studies, randomized trials, or systematic reviews. There have been no studies of the pattern of withdrawals of medicinal products to which deaths have been specifically attributed and the evidence that affects such decisions. Our objectives were to identify medicinal products that were withdrawn after marketing in association with deaths, to search for the evidence on which withdrawal decisions were based, and to analyse the delays involved and the worldwide patterns of withdrawal. METHODS: We searched the World Health Organization's Consolidated List of [Medicinal] Products, drug regulatory authorities' websites, PubMed, Google Scholar, and textbooks on adverse drug reactions. We included medicinal products for which death was specifically mentioned as a reason for withdrawal from the market. Non-human medicines, herbal products, and non-prescription medicines were excluded. One reviewer extracted the data and a second reviewer verified them independently. RESULTS: We found 95 drugs for which death was documented as a reason for withdrawal between 1950 and 2013. All were withdrawn in at least one country, but at least 16 remained on the market in some countries. Withdrawals were more common in European countries; few were recorded in Africa (5.3%). The more recent the launch date, the sooner deaths were reported. However, in 47% of cases more than 2 years elapsed between the first report of a death and withdrawal of the drug, and the interval between the first report of a death attributed to a medicinal product and eventual withdrawal of the product has not improved over the last 60 years. CONCLUSIONS: These results suggest that some deaths associated with these products could have been avoided. Manufacturers and regulatory authorities should expedite investigations when deaths are reported as suspected adverse drug reactions and consider early suspensions. Increased transparency in the publication of clinical trials data and improved international co-ordination could shorten the delays in withdrawing dangerous medicinal products after reports of deaths and obviate discrepancies in drug withdrawals in different countries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for Causality Assessment of Adverse Drug Reactions: A Systematic Review
Agbabiaka, T. B., Savović, J., & Ernst, E. (2008) · Drug Safety · doi:10.2165/00002018-200831010-00003 · Cited by 366
Systematic reviews of adverse effects: framework for a structured approach
Loke, Y. K., Price, D., Herxheimer, A., & the Cochrane Adverse Effects Methods Group (2007) · BMC Medical Research Methodology · doi:10.1186/1471-2288-7-32 · Cited by 253
Thomas, S. H. L., Drici, M. D., Hall, G. C., Crocq, M. A., Everitt, B., Lader, M. H., Jeunne, C. L., Naber, D., Priori, S., Sturkenboom, M., et al. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01563.x · Cited by 67 · cited 1×
“In other cases [21,22], the cause and effect relation was not clearly demonstrated, and there have been controversies about whether such agents should have been removed from the market.”
Background
Cited by
Onakpoya, I. J., Heneghan, C. J., & Aronson, J. K. (2016) · BMC Medicine · doi:10.1186/s12916-016-0553-2 · Cited by 616
Self-citationWITHDRAWN—a resource for withdrawn and discontinued drugs
Siramshetty, V. B., Nickel, J., Omieczynski, C., Gohlke, B.-O., Drwal, M. N., & Preissner, R. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1192 · Cited by 286
RetractedOnakpoya, I. J., Heneghan, C. J., & Aronson, J. K. (2016) · BMC Medicine · doi:10.1186/s12916-016-0735-y · Cited by 171
Self-citationIn silico assessment of adverse drug reactions and associated mechanisms
Ivanov, S. M., Lagunin, A. A., & Poroikov, V. V. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.018 · Cited by 49
Metadata
- Authors
- Onakpoya, I. J., Heneghan, C. J., & Aronson, J. K.
- Venue
- BMC Medicine
- Published
- 2015-02-05
- Volume
- 13
- Issue
- 1
- Pages
- 26-26
- ISSN
- 1741-7015 (ISSN-L)
- OpenAlex
- W2132897534
- Cited by
- 65
- References
- 3
- FWCI
- 16.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis. https://app.cochat.ai/papers/10.1186/s12916-014-0262-7
- The paper
- Onakpoya, I. J., Heneghan, C. J., & Aronson, J. K. (2015). Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis. BMC Medicine. https://doi.org/10.1186/s12916-014-0262-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.